Last checked at 
(Alliance News) - Byotrol PLC said Monday it has seen a "very substantial" increase in demand for the full range of its infection prevention and control technologies over the last seven weeks.
The firm also announced it has entered into a know-how licence and commercial collaboration with infection prevention and contamination control product manufacturer Tristel PLC.
"The formulation combines Tristel's chlorine dioxide chemistry, which is sporicidal meaning that it has the highest level of disinfection efficacy, with Actizone, a Solvay SA technology developed in collaboration with Byotrol and which enables a disinfectant to have long-lasting efficacy on a surface for an eight-hour period after first application. Tristel will incorporate the jointly developed formulation in several packaging formats under the family name 'Tristel8'. These products will be unique worldwide in combining sporicidal efficacy with residual disinfection efficacy," the pair said.
In addition, Byotrol will license two biocidal formulations to Tristel for incorporation in its surface disinfectants range which is branded Cache.
The Byotrol products and formulations give Tristel access to intermediate level disinfectants that are effective against bacteria, viruses and yeasts in accordance with the requirements of European Test Norms, the two said.
The agreement has a duration of ten years and will be exclusive in hospitals in the UK and Ireland and non-exclusive elsewhere. Under the terms of the agreement, Tristel will pay to Byotrol a combination of product supply payments, royalties and fees, based on success but with meaningful minimum guarantee payments to Byotrol each year.
Turning to trading, Byotrol said firm orders currently stand at GBP1.7 million for deliveries to end of June, with many more orders still being processed. The company noted its order book at this time of year typically stands at GBP350,000.
Byotrol said: "We have been working very hard with our contract manufacturers to increase availability of our products and satisfy the exceptional demand. These manufacturers have themselves all been dealing with supply chain constraints, initially and especially in packaging materials (most of which originate in China), and increasingly now in commodity chemicals as the crisis accelerates."
The company now expects to results for the year ending March 31 to exceed expectations.
We believe that infection prevention and control technologies are set to become ever more important in today's world, even after Covid-19 is brought under control."
"The Byotrol team is working very hard with customers and suppliers to meet the huge demand for our excellent infection control products. We are currently selling everything we can make, and are investigating every opportunity to increase capacity further," Chief Executive David Traynor said.
He added: "We believe that infection prevention and control technologies are set to become ever more important in today's world, even after Covid-19 is brought under control."
Tristel noted it also expects its demand to increase due to the spread of Covid-19.
Shares in Byotrol closed 34% higher in London on Monday at 4.79 pence each. Tristel closed 18% higher at 446.00 pence.
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
